Progesterone capsules contain micronized bioidentical progesterone, a hormone that is molecularly identical to the progesterone naturally produced by the human body. Micronization is a process that reduces progesterone particles to a very small size, significantly improving absorption and bioavailability when taken orally. Progesterone plays essential roles beyond reproductive function, including regulation of the menstrual cycle, support of sleep quality, modulation of mood and anxiety, maintenance of bone density, and counterbalancing the effects of estrogen throughout the body.

Progesterone capsules are available in two formulations designed to meet different therapeutic needs. Immediate-release (IR) capsules deliver progesterone rapidly into the bloodstream, creating higher peak levels that may be beneficial for sleep support and acute symptom management. The sedative properties of progesterone are more pronounced with IR formulations, making them particularly useful when taken at bedtime for women experiencing sleep disturbances. Sustained-release (SR) capsules are formulated to release progesterone gradually over an extended period, providing more stable hormone levels throughout the day with reduced sedative effects. This formulation may be preferable for women who need consistent progesterone levels without pronounced drowsiness.

During perimenopause and menopause, progesterone levels typically decline earlier and more dramatically than estrogen, often contributing to irregular cycles, sleep disturbances, mood changes, anxiety, and symptoms of estrogen dominance. For postmenopausal women receiving estrogen therapy, adequate progesterone is essential for protecting the endometrial lining and reducing the risk of uterine hyperplasia or cancer. Your healthcare provider will determine which formulation—immediate-release or sustained-release—is most appropriate based on your symptoms, lifestyle, and treatment goals.

Progesterone capsules are taken orally with water, typically once daily. IR formulations are usually taken in the evening or at bedtime due to their sedative properties, while SR formulations may be taken at any consistent time of day as directed by your provider. Many women taking IR progesterone at bedtime notice improvements in sleep quality within the first week of treatment. Other symptoms such as mood stability, anxiety reduction, and menstrual regulation typically improve over 4-8 weeks as hormone levels stabilize.

Individual response varies based on baseline hormone levels, symptom severity, formulation type, and dosing. Women taking IR formulations may initially experience drowsiness or dizziness, which typically indicates effective absorption and often lessens with continued use. SR formulations generally produce less pronounced sedation while maintaining therapeutic hormone levels. Your provider may recommend hormone level testing to monitor response and optimize dosing. Some women may experience mild side effects during the initial adjustment period, which typically resolve as the body adapts to therapy.

Progesterone capsules are generally well-tolerated. Potential side effects may include drowsiness, dizziness, headache, breast tenderness, bloating, or mood changes. IR formulations may cause more pronounced sedation. Progesterone is contraindicated in individuals with active blood clots, liver disease, undiagnosed vaginal bleeding, or known hormone-sensitive malignancies. Use during pregnancy should only occur under direct provider supervision. Inform your provider of all medications and supplements, as progesterone may interact with certain drugs. Women with an intact uterus using estrogen therapy require progesterone for endometrial protection. Avoid driving or operating machinery if you experience drowsiness, particularly with IR formulations.